A Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors

Summary

This is a 2-part, first-in-human, open-label study to determine the safety, tolerability and preliminary efficacy of KIVU-305, a CEACAM5-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.

Timeline

Start

2026-06

Primary completion

2027-12

Completion

2029-12

Drugs

Indications